Previous 10 | Next 10 |
Nano cap Fibrocell Science (NASDAQ: FCSC ) is up 17% premarket on increased volume in reaction to the FDA's designation of Regenerative Medicine Advanced Therapy (RMAT) status for gene therapy FCX-007 for the treatment of a rare inherited skin disorder called recessive dys...
EXTON, Pa., May 29, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the R...
Fibrocell Science, Inc. (FCSC) Q1 2019 Earnings Conference Call May 15, 2019 8:30 AM ET Company Participants Karen Casey – Investor Relations Manager John Maslowski – President and Chief Executive Officer Sean Buckley – Vice President-Business Administration ...
The following slide deck was published by Fibrocell Science, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Fibrocell Science (NASDAQ: FCSC ): Q1 GAAP EPS of -$0.40 misses by $0.06 . More news on: Fibrocell Science, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
EXTON, Pa., May 15, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the first quarter ended March 31, 2019 and re...
EXTON, Pa., May 09, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2019 and recen...
Fibrocell Science ( FCSC ) was able to establish a partnership with privately held Castle Creek Pharmaceuticals . This partnership will help Fibrocell to advance its gene therapy product FCX-007 to treat patients with a rare life-threatening disease known as recessive dystrophic epidermolys...
Bristow Group (NYSE: BRS ) -38% after skipping interest payment. More news on: Bristow Group Inc., ChinaNet Online Holdings, Inc., ATA Inc., Stocks on the move, Read more ...
Gainers : Fibrocell Science (NASDAQ: FCSC ) +52% . Bio-Path Holdings (NASDAQ: BPTH ) +40% . Vectrus (NYSE: VEC ) +27% . Electronics for Imaging (NASDAQ: EFII ) +27% . SSLJ.com (NASDAQ: SSLJ ) +22% . ATA (NASDAQ: ATAI ) +21% . Advanced Disposal Services (NYSE: ADSW ) +19% . Amy...
News, Short Squeeze, Breakout and More Instantly...
Fibrocell Science Inc. Company Name:
FCSC Stock Symbol:
NASDAQ Market:
PARSIPPANY, N.J. , Sept. 12, 2019 /PRNewswire/ -- Castle Creek Pharmaceutical Holdings, Inc. ("CCP Holdings") today announced it has reached an agreement to acquire Fibrocell Science, Inc. (Nasdaq: FCSC), a cell and gene therapy company focused on transformational autologous cell-bas...
- Total consideration of $ 63.3 million, including repayment of debt and other financial instruments - - Acquisition expected to close in the fourth quarter of 2019 - - Further strengthens Castle Creek Pharmaceuticals as a leader in dermatology - EXTON, Pa., Sept. 12, 2019 (GL...
- Company to Host Conference Call and Webcast on Thursday, August 15 at 8:30 a.m. EDT - EXTON, Pa., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissu...